UPDATE: Morgan Stanley Downgrades Moderna (MRNA) to Equalweight

Moderna (MRNA) Declines 8%

Moderna (NASDAQ: MRNA) Declines 8%

Moderna (MRNA) calls more active than puts, IV above 100

Moderna (NASDAQ: MRNA) 30-day option implied volatility is at 108; compared to its 52-week range of 51 to 173. Call put ratio 1.9 calls to 1 put.

Jefferies Downgrades Moderna (MRNA) to Hold on Stock Run-Up and Expectations

(Updated - December 15, 2020 5:06 PM EST)

(updated to add analyst comments)

Jefferies analyst Michael Yee downgraded Moderna (NASDAQ: MRNA) from Buy to Hold with a $150 price target (from $90), saying they are lowering their rating to Hold on the significant stock run and... More

FDA Intends to Grant Emergency Authorization of Moderna (MRNA) Covid Vaccine on Friday - NYT, Citing Sources

FDA Intends to Grant Emergency Authorization of Moderna (NASDAQ: MRNA) Covid Vaccine on Friday - NYT, Citing Sources

FDA Posts Briefing Document for Moderna (MRNA) Covid-19 Vaccine

FDA Posts Briefing Document for Moderna (NASDAQ: MRNA) Covid-19 Vaccine

Moderna (MRNA) Confirms Supply Agreement with the Ministry of Health to Supply Singapore with mRNA Vaccine Against COVID-19

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today confirmed that the Company concluded an agreement with the Ministry of Health of Singapore to supply mRNA-1273, Modernas vaccine candidate against COVID-19, to support... More

Public Comfort with Vaccination Grows to 52% from 47% in November - Jefferies

Public comfort with Covid-19 vaccination has continued to increase, according to the latest survey conducted by Jefferies. This month, 52% of Americans said they plan to get a vaccine in the next 3-6 months, which is higher than 47% last month.

Jefferies analyst Michael Yee says that the banks analysis shows that capacities of Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) are... More

Moderna (MRNA) Expects Approval of Vaccine in EU Jan. 12: Stuttgarter Zeitung - Bloomberg

Moderna (NASDAQ: MRNA) Expects Approval of Vaccine in EU Jan. 12: Stuttgarter Zeitung - Bloomberg

Moderna (MRNA) IV at 111 amid Covid vaccine headlines

Moderna (NASDAQ: MRNA) 30-day option implied volatility is at 111; compared to its 52-week range of 51 to 173 amid Covid vaccine headlines. Call put ratio 2.4 calls to 1 put.